Clients Recognize Integration, Scalability and Innovation Strengths
NextGen Enterprise was praised for its integration capabilities, as well as scalability, and innovation and optimization. NextGen Healthcare scored high marks for trust, accountability, transparency and ethics. Further, NextGen Enterprise scored in the highest client satisfaction category overall, receiving a designation of “overwhelmingly exceeds expectations.”
“The Black Book survey results are a reflection of our commitment to our clients’ success,” said
NextGen Healthcare Ranked No. 1 overall and took the top spot in 12 categories, including:
- Best-of-Breed Technology: EHR vendor technology elevates customers via capabilities, equipment, processes, deliverables, professional staff, leadership, quality assurance and innovative initiatives.
- Integration: The vendor supports interfaces so information can be shared between necessary applications. Solutions are easily integrated to existing backend systems as needed and Health Information Exchange (HIE)-feasible.
- Innovation & Optimization: Clients believe that their vendor’s technology is helping them manage practices more effectively, generate accurate records and reimbursement billings, and cut their overhead.
- Support and Customer Care: Account management program meets client needs. Customer service and relationship satisfaction is manifested through significant flagship clients, as well as smaller and newest customers similarly.
To read the full report, visit: nextgen.com.
A total of 3,294 physicians, clinicians, and specialists, as well as administrative, IT and finance leaders from 3,005 practices, groups, clinics, and facilities participated in the 2022 multiple provider practice EHR PM RCM surveys. Collected data is audited by internal and external parties to verify completeness, accuracy and client anonymity and then reported with a 95% confidence level. Learn more at blackbookmarketresearch.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005838/en/
Investor Relations Contact